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Abstract
Background: Introduction of pneumococcal vaccines in Nigeria is a priority as part of the Accelerated Vaccine Introduction
Initiative (AVI) of the Global Alliance for Vaccines and Immunisation (GAVI). However, country data on the burden of
pneumococcal disease (IPD) is limited and coverage by available conjugate vaccines is unknown. This study was carried out
to describe the pre vaccination epidemiology and population biology of pneumococcal carriage in Nigeria.
Methods: This was a cross sectional survey. Nasopharyngeal swabs (NPS) were obtained from a population sample in 14
contiguous peri-urban Nigerian communities. Data on demographic characteristics and risk factor for carriage were
obtained from all study participants. Pneumococci isolated from NPS were characterised by serotyping, antimicrobial
susceptibility and Multi Locus Sequencing Typing (MLST).
Results: The prevalence of pneumococcal carriage was 52.5%. Carriage was higher in children compared to adults (67.4% vs.
26%), highest (<90%) in infants aged ,9 months and reduced significantly with increasing age (P,0.001). Serotypes 19F
(18.6%) and 6A (14.4%) were most predominant. Potential vaccine coverage was 43.8%, 45.0% and 62% for PCV-7, PCV-10
and PCV-13 respectively. There were 16 novel alleles, 72 different sequence types (STs) from the isolates and 3 Sequence
Types (280, 310 and 5543) were associated with isolates of more than one serotype indicative of serotype switching.
Antimicrobial resistance was high for cotrimoxazole (93%) and tetracycline (84%), a third of isolates had intermediate
resistance to penicillin. Young age was the only risk factor significantly associated with carriage.
Conclusions: Pneumococcal carriage and serotype diversity is highly prevalent in Nigeria especially in infants. Based on the
coverage of serotypes in this study, PCV-13 is the obvious choice to reduce disease burden and prevalence of drug resistant
pneumococci. However, its use will require careful monitoring. Our findings provide sound baseline data for impact
assessment following vaccine introduction in Nigeria.
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Introduction
Pneumonia is one of the leading causes of mortality in children
,5 years old. It is responsible for 1.6 million of 8.8 million
annual deaths in this age group [1] with 50% occurring in sub-
Saharan Africa [2]. Streptococcus pneumoniae (pneumococcus),
accounts for 30–50% of pneumonia-related deaths [3,4,5].
Pneumococcus is also a major cause of acute otitis media
(AOM), bacteraemia, meningitis and sinusitis particularly in
developing countries [5].
There are over 91 serotypes of pneumococci and worldwide, 6–
11 serotypes are responsible for $70% of invasive disease (IPD) in
children ,5 years old [6]. The distribution of pneumococcal
capsular serotypes found in nasopharyngeal (NP) carriage, and
IPD vary by age, geography and socioeconomic status [7,8,9].
Pneumococcus is also part of the normal microbial flora in the
nasopharynx, its main reservoir. Although harmless and asymp-
tomatic by itself, carriage is a precondition for invasive and non-
invasive disease and is associated with the incidence of AOM,
bacteraemia and pneumonia [10,11]. Pneumococcal carriage is
highly prevalent in developing countries particularly among
children aged ,5 years. Carriage in ,5 years age group varies
from 44–90% in Papua New Guinea, Fiji, Indonesia, Venezuela
and The Gambia [12,13,14,15].
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Since vaccination is the most effective public health tool to
prevent IPD, pneumococcal conjugate vaccines (PCVs) containing
7, 10 and 13 serotypes have been developed although PCV-7 is
being replaced by PCV-10 and -13 because it contains limited
serotypes. Unlike the 23 serotype-containing polysaccharide
vaccine, PCVs are more immunogenic in young children, induce
immunological memory and provide serotype-specific protection
against pneumococcal carriage. Although they contain serotypes
most associated with disease and antimicrobial resistance world-
wide, variation of serotypes geographically and antimicrobial
resistant strains prevent universal protection. In addition,
replacement in carriage and invasive disease by non-vaccine
containing and drug resistant serotypes of pneumococci occurs
with use of PCVs [16].
In many countries needing PCV the most, data on the burden
of pneumococcal carriage and disease; as well as the prevalent
serotypes and coverage by PCVs is limited or unknown. Nigeria is
one of the 10 countries where two-thirds of all deaths due to
pneumonia in children,5 years occur [17,18]. It is also one of the
15 countries with the highest estimated number of cases of clinical
pneumonia [3]. Over 30 years ago, pneumococci serotypes 1, 2, 3
and 5 were the serotypes associated with IPD in children and
adults in North East, Nigeria. [19] A decade later, Silverman et. al.
[20] found 51% of isolates from children with severe pneumonia
were pneumococci. More recently, a small study in Eastern
Nigeria found 69% pneumococci carriage rates in children
,5years attending routine paediatric clinics [21]. And in a
hospital based surveillance of invasive bacterial infections,
pneumococcus was implicated in the majority of pneumonia,
meningitis and bacteraemia in the children studied [22]. Existing
data on pneumococcal carriage and disease in Nigeria have
limitations including small sample sizes, poor yield of pneumococci
and/or that very few isolates are serotyped and results from earlier
studies are out of date. Consequently, the current prevalence of
serotypes in carriage and disease is largely unknown in Nigeria.
Baseline pneumococcal carriage and invasive rates data are crucial
for assessing the impact of vaccination and for monitoring serotype
changes and antimicrobial resistance patterns.
We investigated pneumococcal carriage in a Nigerian popula-
tion to determine carriage rates, prevalent serotypes; theoretical
coverage of pneumococcal conjugate vaccines and molecular
epidemiology of pneumococci in this population.
Methods
Study area and population
The Lagos University Teaching Hospital Primary Health Care
and Rural Medicine Centre (LUTH PHC), Pakoto village is
approximately 70 kilometres from Lagos, Nigeria. This health
centre serves all communities within a 10 km radius covering two
local government areas (LGAs) and it was the base for this study.
Pakoto is one of 250 communities in Ifo LGA, Ogun State,
Nigeria. The total population is 350,000 (2006 National
Population Census, Nigeria). Majority of the inhabitants are
Yoruba.
Design and Sample Size considerations
This was a cross sectional survey. The target sample was a range
of 384–518 children aged ,5 years required to estimate the
prevalence of pneumococcal carriage with a precision of 5% (with
95% confidence) and 80–90% power. Since prevalence of carriage
in the whole community has an impact on prevalence of carriage
in children aged ,5 years and vice versa, a sample including all
age groups was preferred. To obtain a representative sample in an
area with unknown age distribution, all consenting children aged
,5 years; 1 in 3 persons aged 5–49 years and all those aged .50
years up to 1000 subjects were swabbed. Even if the proportion of
children aged ,5 years in the study communities was less than
25%, the sampling was designed to give an expected ratio of
subjects of 25:21:11 (i.e. at least 440 ,5 years). Communities
selected for the study were within a 5 km radius of the health
centre.
Eligibility
All consenting adults and children ordinarily resident in the
study area were eligible for enrolment.
Ethical Considerations
The Ethics Committees of the Lagos University Teaching
Hospital, Lagos, Nigeria, the London School of Hygiene and
Tropical Medicine, UK approved this study and acknowledge-
ment received from the Gambian Government and MRC joint
ethics committee. Parents/guardians of minors and every adult
participant gave written informed consent before participation in
study. Those 15–17 years old gave assent was in addition to
written consent given by parents/guardians.
Data and Sample collection and identification of
pneumococcus
A questionnaire was administered to each subject (adolescent
with their parents/guardians and adults) or to their parent or
guardian (for minors) by a trained field worker to obtain
demographic, personal, clinical, general and age-specific risk
factors data. The risk factors for which data was obtained via
questionnaire were household smoking, number of ,5-year old
residents in household, household cooking fuel, breastfeeding in
children aged ,6 months, antibiotic use, gender, age, ethnicity,
location, overcrowding, and socioeconomic status.
All procedures (swabbing, storage and culture) were carried out
using standard methods recommended by the World Health
Organization (WHO) [23]. Briefly, samples were obtained with a
deep nasopharyngeal swab (NPS) using calcium alginate swab tips
on a flexible aluminium shaft (Fisher brandH, Fisher Scientific,
Pittsburgh, USA). NPS were placed inside Skim milk-tryptone-
glucose-glycerin (STGG) transport media [24] and transported
within 8 hours of collection for storage at 230uC before
transportation in dry ice to the MRC. Samples were cultured at
the MRC Microbiology Laboratory on gentamicin 5% sheep
blood agar incubated at 37uC in 5% CO2. Samples of all typical S.
pneumoniae colonies obtained by sweep method from the plates
were subjected to pneumococcal identification methods of a-
haemolysis, colony morphology and ethylhydrocupreine hydro-
chloride (optochin). Bile solubility testing was applied to isolates
with intermediate optochin sensitivity. Serotyping was done by
latex agglutination using serotype specific antisera (Statens Serum
Institute, Denmark). Confirmation of equivocal isolates was by
molecular serotyping using multiplex PCR [25]. As S. pneumoniae
serotype 6A cross-reacts serologically with serotype 6C, we tested
all serotype 6A isolates by multiplex PCR to differentiate serotype
6A from 6C as previously described [26]. Isolates that were non-
typeable by these methods were listed as non-typeable pneumo-
coccus.
Randomly selected isolates (201) had to microbial susceptibility
tests to Penicillin G (PG), Cefotaxime (CT), Tetracycline (TC),
Trimethoprim/sulfamethoxazole (TS), Erythromycin (E) and
Chloramphenicol (CL) using E-tests (AB Biodisk, Solna, Sweden).
Minimum inhibitory concentrations (MICs) with resistance and
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sensitivity according to the interpretive criteria provided in the
product insert were recorded. Resistant Isolates were those with
MICs above the threshold for sensitivity.
The MRC Unit, submits to the external quality assurance
programme of the United Kingdom National External Quality
Assessment Service [27] and is a World Health Organization
(WHO) regional reference laboratory for invasive bacterial
pathogens.
Multi locus sequencing typing (MLST)
MLST was performed as previously described [28]. Sequence
types (STs) were analyzed for relatedness using the eBURST v3
program. [29] Cluster analysis of allelic profiles was performed
using a categorical coefficient and a graphic method called a
minimum spanning tree with Bionumerics software  (version 4.0;
Applied Maths, Sint-Martens-Latem, Belgium).
Data Management and Statistical Analysis
All data were double entered into an Access relational database.
Statistical analyses were performed using Stata 11.1 (Stata Corp
LP, College Station, Texas). The main outcome variable was
prevalence of pneumococcal carriage. The secondary outcomes
were genetic structure of and serotypes found in carriage, their
antibiotic susceptibility and risk factors (both general and specific)
associated with carriage. Analysis of carriage was done with
‘person’ as unit of analysis while analysis of serotypes and
antibiotic resistance was done with ‘isolate’ as unit of analysis.
The exposures considered were household smoking, number of
,5-year old residents in household, household cooking fuel,
breastfeeding in children aged ,6 months, antibiotic use, gender,
age, ethnicity, location, overcrowding, and socioeconomic status.
Socioeconomic status was assessed using a modification of the
socio-economic index score validated for Nigeria [30]. Multivar-
iate analyses were carried out using logistic regression. Analysis of
each exposure/risk factor was adjusted for sex and age and
adjusted odds ratios for the presence of carriage were obtained
separately for each risk factor.
Random effects logistic regression models were used to adjust
for the effect of clustering on outcomes by location.
Results
General characteristics of study population
Out of 1025 consenting participants, 98.0% (1005) had useable
NPS that were cultured. Their median age was 4.4 (interquartile
range [IQR] 1.3–30) years. They were predominantly female (652,
63.8%) and Yoruba (952, 92.8%). As planned, there were more
children (654, 63.8%) than adults were. A history of antibiotic use
in sampled children was obtained in 100 (15.6%) of 641 children
and from 76 out of 361 (21.1%) adults. Overall, 176 (17.5%) of
total study population had taken a course of antibiotics at least 1
month prior to sampling. Antibiotics were obtained mostly by self-
prescription and purchased from drug stores (66.7% [95% CI
54.8–77.1%], 50 of 75).
Prevalence of carriage
Pneumococcus was identified in swabs from 528 of 1005
subjects. The prevalence of carriage was 52.5% (95% Confidence
Interval [CI]: 49.4–55.7%). As seen in figure 1, the prevalence of
carriage reduced significantly with increasing age (x2 = 165.7,
p,0.0001 for trend).
Pneumococcal carriage was higher in children (those ,18
years), 434 of 644 (67.4% [95% CI 63.6–71%]) compared to
adults, 94 of 361 (26% [95% 21.6–30.9%] and this difference was
significant (p,0.001). Carriage was highest (244 of 328) in
children aged ,2 years i.e. 74.4% (69.3%–79.0%). As shown in
figure 2, pneumococcal carriage steadily increased from 47.8%
very early in infancy (,2.9 months) to peak values of 89.6%
between 6–9 months and this trend was statistically significant
(x2 = 15.3, p= 0.0001). There was a higher prevalence of
pneumococcal carriage in males compared to females (60.3% vs.
48.0%, p,0.001). However, when subjects were stratified into
adults or children, this difference was no longer statistically
significant. Pneumococcal carriage was also unrelated to ethnicity
(52% in Yoruba vs. 53% in other ethnic groups, p = 0.9).
Serotypes, clones in carriage and theoretical vaccine
coverage
Forty-two (42) serotypes of pneumococcus were identified, while
17 isolates (3.2%) were non-typeable (NT). The distribution of
serotypes also varied by age group with almost 80% of all serotypes
carried by children ,5 years diminishing to <50% in the older
age groups as shown in Table 1. The top 10 serotypes found and
the age groups related differences in the ranking of prevalence
serotypes are shown in Table 1. There were 3–5 vaccine serotypes
within the top 10 ranked serotypes in all age categories. The fewest
number (3) was found in the 5–14 years category. About 9.3%
carried multiple pneumococcal serotypes (49 of 528). Carriage of
multiple pneumococci was associated mainly with serotypes 19F
(2.7%) and 6A (2.3%) while serotypes 6B and 23F together were
associated with carriage of multiple serotypes in 2.5% of subjects.
Serotypes9V, 14, 18C, 3 and 15C accounted for 2–4% of
overall pneumococcal isolates, while other serotypes not previously
mentioned made up less than 2% of all serotypes found.
The theoretical coverage for the earliest available conjugate
vaccine-PCV7, was poor for all age categories ranging from
30.2%–49.1% and there was very little difference between the
coverage offered by the newer PCV10 when compared to PCV7
(Table 1). In children aged ,2 years, coverage was identical for
Figure 1. Prevalence of pneumococcal carriage by age group in
a peri-urban Nigerian Community.
doi:10.1371/journal.pone.0030548.g001
Figure 2. Prevalence of nasopharyngeal carriage of pneumo-
coccus by infant age category in a peri urban Nigerian
Community.
doi:10.1371/journal.pone.0030548.g002
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PCV7 and PCV10, 34.8% and was 61.7% for PCV13. For all
PCVS, coverage was highest for the ,5 years and $15–39 years
age group as seen in Table 1.
Population snapshot of pneumococcal isolates by MLST:
discovery of novel alleles
MLST was performed on 99 pneumococcal isolates represent-
ing 29 different serotypes selected randomly from the 528
pneumococcal isolates. We found 16 novel alleles [(aroE (172,
176, 177), gdh (206, 260, 261, 262); gki (260, 261); recP (154), spi
(239, 244), xpt (346, 354, 355), ddl 406)] and with 72 (72.7%)
different sequence types (ST) as shown in table S1. e-burst analysis
using the stringent 6/7 identical loci definition grouped these STs
into 9 clonal complexes of closely related strains and 45 singletons
(diagram not shown). The higher number of singletons (83.3%)
identified in the study i.e. STs with no close relatives reflects a
highly diverse pneumococcal population structure in Nigeria,
which is different from those STs in the global MLST database
(figure 3). Three STs (280, 310 and 5543) were found to be
associated with isolates of more than one serotype indicative of
serotype switching (see Table S1).
Antimicrobial susceptibility
A random selection of 201 pneumococcal isolates was tested for
susceptibility to the following antibiotics; Erythromycin (E),
Tetracycline (TC), Cefotaxime (CT), Trimethoprim-Sulphameth-
oxazole (TS), Penicillin G (PG) and Chloramphenicol (C). Isolates
were only fully susceptible to erythromycin and 1 (0.5%) isolate
had high-level resistance to CT otherwise others were fully
susceptible (see table 2). Of all the isolates resistant to tetracycline,
75.2% (151) and 9.0% (18) had high level and intermediate
resistance respectively. The highest level of resistance overall was
seen with TS with high level and intermediate resistance in 110
(54.7%) and 77 (38.3%) respectively. Only intermediate resistance
to Penicillin G was seen as shown in table 2.
Antibiotic use was associated with age (p,0.001) and history of
prior ingestion was highest in those aged ,5 years (93 of 523,
17.8%) and aged.40 years (40 of 139, 29%); and least in the 5–14
years age category (6 of 125, 4.8%). Overall, there were no
differences in prevalence of carriage by history of antibiotic use
(52.3% vs. 54.0%, p= 0.7). When children (,18 years) were
compared to adults, no differences in carriage by antibiotic use
were seen as well.
Assessment of risk factors for carriage
In multivariable analysis, pneumococcal carriage was adjusted
for age, gender, overcrowding, predominant household cooking
fuel, and total household residents aged ,5 years. At the level of
the individual, age and overcrowding were significantly associat-
ed with pneumococcal carriage. The odds of pneumococcal
carriage in the ,5 years age group was 7 times more than in
those aged .40 years. They also had 2.5 times the odds of
carriage found in the 5–14 years age group. As shown in table 3,
the odds of pneumococcal carriage increased significantly with
reducing age and this trend was significant (x2 = 135.7, p,0.001).
There was also a significant trend towards increased carriage with
number of inhabitants (i.e. 4 or more occupants per room) in a
household (x2 = 4.3, p = 0.04). There was some evidence for
reduced carriage with use of other cooking fuel (mainly charcoal
and bottled gas) apart from kerosene but this was not statistically
significant.
On adjusting the data for clustering by location in a random
effect logistic regression model, age remained the key risk factor for
carriage at community level. The evidence for an association
between overcrowding and pneumococcal carriage weakened
when data was adjusted for clustering.
Table 1. Pneumococcal Carriage and approximate vaccine coverage by age.
All ,5years 5–14 years .15–39years $40
Numbers with carriage (n) 528 375 63 57 33
Carriage (%) 52.5 71.0 11.9 10.8 6.3
Number of different serotypes seen 42 33 21 21 19
Top 10 Serotypes
1 19F (94) 19F (71) 19F (10) 19F (11) 11 (3)
2 6A (76) 6A (65) 11 (7) 6A (7) 23F (3)
3 6B (72) 6B (60) NT (6) 23F (6) 3 (3)
4 23F (37) 23F (27) 18C (5) 11 (4) 6B (3)
5 11 (27) 15B (14) 6B (5) 18C (4) 12 (2)
6 15B (21) 11 (13) 3 (4) 6B (4) 13 (2)
7 3 (19) 14 (13) 6A (4) 15B (3) 17 (2)
8 NT (17) 19A (10) 15B (3) 3 (2) 19F (2)
9 18C (15) 3 (10) 20 (3) 4 (2) 7C (2)
10 9V (15) 9V (10) 21 (3) 7F (2) 9V (2)
Total isolates represented by top 10 serotypes 74.4% 78.1% 79.4% 78.9% 72.7%
PCV-7 Serotypes 231 (43.8%) 173 (46.1%) 19 (30.2%) 28 (49.1%) 11 (33.3%)
PCV-10 Serotypes 235 (44.5%) 174 (46.4%) 20 (31.8%) 30 (52.6%) 11 (33.3%)
PCV-13 Serotypes 325 (61.6%) 264 (70.4%) 27 (42.9%) 38 (66.7%) 14 (42.4%)
PCV-pneumococcal conjugate vaccine; NT-Non Typeable; PCV7 serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F; PCV10 serotypes: PCV7+ 1, 5, 7F; PCV13 serotypes:
PCV10+ 3, 6A, 19A.
doi:10.1371/journal.pone.0030548.t001
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Discussion
This study investigated pneumococcal carriage in a Nigerian
population to determine carriage rates, prevalent serotypes,
theoretical coverage of available pneumococcal conjugate vaccines
and population biology of isolated pneumococci. Since recently
acquired pneumococci in carriage are usually the primary source
of serotypes that cause invasive disease, carriage of pneumococcus
can provide information on prevalence of antimicrobial resistance
and some insight into need for vaccines and potential impact of
selected vaccine on IPD. [10,31]
Nigeria is one of the countries in the west sub-Saharan Africa
region that currently plans to introduce one of the available PCVs.
This may likely be PCV-13 if the example of other African
countries (Mali, Rwanda, Gambia and Sierra Leone) is followed. If
introduced, the likely benefit of this vaccine is currently unknown
and baseline data to inform expected changes or trends in
pneumococcal carriage and IPD are unavailable. We hope this
study will address some of these knowledge gaps. To our
knowledge, this is the first investigation into the risk factors and
population structure of carried pneumococcal in Nigeria.
The prevalence of pneumococcal carriage varies within country
and setting ranging from ,10% in some developed countries like
Italy and France [32,33,34] to values .50% in indigenous
children in developed countries and among populations in
developing countries [13,15,35]. We found high levels of
pneumococcal carriage in Nigeria as described in similar settings
[12,14,36,37]. The higher prevalence of pneumococcal carriage in
Figure 3. Clustering of STs by use of the minimum spanning tree. Each circle represents an ST. The area of each circle corresponds to the
number of isolates. Thick, short, solid lines connect single locus variants; thin longer solid lines connect double locus variants and broken lines
connect three or more locus variants. Texts in red and inside the circles are the serotypes.
doi:10.1371/journal.pone.0030548.g003
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children especially young infants compared to adults is also
consistent with reports in the literature [14]. These findings are
consistent with those from a smaller study of infants in South East,
Nigeria [21].
The 42 pneumococci serotypes found in this study population
provide the first detailed description of the repertoire of carried
pneumococcal serotypes in Nigeria. The most common serotypes
were 19F, 6A, 6B, 23F, 11 and 15B. Interestingly, these are among
the most common serotypes reported in carriage studies in similar
settings [14,38]. Pneumococci serotypes carried by children ,5
years are the major source of transmission to older children and
adults within households and communities [28]. Vaccination with
PCVs directly reduces carriage thus reducing transmission and
there is a herd effect or benefit to communities among the
unvaccinated populations [39]. Our findings here of high carriage
rates especially in infants and children ,2 years highlights the
potential impact of PCVs on carriage and community transmission
of pneumococcus if introduced in Nigeria.
Table 2. Antimicrobial resistance pattern (%) for most common and vaccine containing serotypes found in pneumococcal carriage
in Nigeria.
Penicillin TMP-SMX Tetracycline Cefotaxime Erythromycin Chloramphenicol
Overall (201) 62 (30.9) 187 (93.0) 169 (84.1) 1 (0.5) 0 (0.0) 17 (8.5)
Top 10 Serotypes
19F (33) 13 (39.4) 30 (90.9) 28 (84.8) 1 (3.0) 0 (0.0) 2 (6.1)
6A (31) 8 (25.8) 31 (100) 29 (93.6) 0 (0.0) 0 (0.0) 3 (9.7)
6B (26) 4 (15.4) 24 (92.3) 25 (96.2) 0 (0.0) 0 (0.0) 5 (19.2)
23F (16) 4 (25.0) 16 (100.0) 13 (81.3) 0 (0.0) 0 (0.0) 0 (0.0)
11 (16) 2 (12.5) 13 (81.2) 6 (37.5) 0 (0.0) 0 (0.0) 2 (12.5)
15B (7) 1 (14.3) 7 (100.0) 7 (100.0) 0 (0.0) 0 (0.0) 1 (14.3)
3 (7) 6 (85.7) 7 (100.0) 7 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
NT (9) 6 (66.7) 9 (100.0) 8 (88.9) 0 (0.0) 0 (0.0) 1 (11.1)
18C (3) 0 (0.0) 3 (100.0) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
9V (4) 0 (0.0) 4 (100.0) 4 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
PCV-7 Serotypes (81) 26 (29.9) 82 (94.3) 77 (88.5) 1 (1.2) 0 (0.0) 6 (6.9)
PCV-10 Serotypes (88) 26 (29.6) 83 (94.3) 78 (88.6) 1 (1.1) 0 (0.0) 6 (6.8)
PCV-13 Serotypes (123) 40 (32.5) 118 (95.9) 111 (90.2) 1 (0.8) 0 (0.0) 7 (5.7)
doi:10.1371/journal.pone.0030548.t002
Table 3. Multivariable odds ratios determined by logistic regression for pneumococcal carriage and risk factors.
Risk factor *OR (95% CI) P- value **OR (95% CI) p-value
Age group (years)
$40 1.0 1.0
15–39 1.1 (0.64–1.81) ,0.001 1.1 (0.65–1.91) 0.70
5–14 2.9 (1.69–5.03) ,0.001 2.9 (1.63–5.0) ,0.001
,5 7.1 (4.53–11.03) ,0.001 7.4 (4.60–11.85) ,0.001
Gender
Female 1.0 1.0
Male 1.1 (0.79–1.44) 0.65 1.1 (0.81–1.48) 0.57
Predominant cooking fuel
Kerosene 1.0 1.0
Other 0.4 (0.17–1.12) 0.08 0.5 (0.18–1.16) 0.10
Overcrowding index
#3 1.0 1.0
$4 1.3 (1.02–1.83) 0.03 1.3 (0.97–1.78) 0.07
Number of resident under fives
0 1.0 1.0
$1 0.8 (0.60–1.01) 0.14 0.8 (0.61–1.11) 0.20
*OR-Odds Ratio from Logistic regression model.
**Adjusted for clustering.
doi:10.1371/journal.pone.0030548.t003
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Although data on serotypes implicated in IPD in Nigeria is
limited, serotypes 19F, 4 and 5 were found in a recent report on
surveillance of IPD [22] and serotypes 1, 2, 3 and 5 were reported
in children ,12 years over 30 years ago [19]. Since a third of
isolates found in this carriage study belong to this group of
serotypes previously reported to be associated with IPD in Nigeria,
this implies IPD will be reduced significantly by introducing PCV-
13 that contains these serotypes. However, we did not find any
serotype 5 isolate and serotype 1 was only isolated in 2 subjects
despite their frequent isolation in IPD [40,41]. Since they are both
are rarely seen or occur at very low frequencies in carriage, our
findings are not surprising [14,40]. Despite the low numbers of
serotypes 1 and 5 found, 4 of the top 6 serotypes in this study are
included in the list of the 7 serotypes most commonly found in IPD
globally thus confirming the need to introduce PCV in this setting
[6].
The serotype coverage for PCV-7 (44%) is limited in Nigeria
and similar settings because of the few serotypes it contains. In
particular, it does not contain serotypes 1 and 5 that have been
implicated 25–30% of IPD found in low resource settings [41].
Although some countries are switching from PCV-7 to PCV-10,
PCV-10 did not provide any significant added coverage over
PCV-7 in our study population based on the prevalent serotypes
we found in carriage. In contrast, the coverage for the PCV-13 was
62% in our study population as a whole and 70% in those ,5
years. Our finding of highest serotype coverage for all licensed
PCVs in very young children who bear most of the morbidity and
mortality associated with IPD is evidence for the potential benefit
of introducing PCVs into the Nigerian immunization schedule for
children. The evidence from our data confirms PCV-13 as the best
option. Taken together, our findings here in carriage i.e. 70%
coverage of serotypes in children ,5 years and the available
information on prevalent serotypes in IPD suggest introduction of
PCV-13 will significantly reduce morbidity and mortality
associated with pneumococcus in the short and long term. The
communal benefits of PCVs even of limited serotype coverage to
all age groups in similar settings has been well described [42].
Although replacement by non-vaccine serotypes in both
carriage and disease occurs following prolonged routine use of
PCVs [16], this has not diminished the gains associated with
introduction of PCV. Rather, this highlights the need for
introduction of routine surveillance to confirm continued utility
of PCV-13 once widely deployed in Nigeria.
MLST analysis shows not only a higher proportion of novel STs
but also a highly diverse pneumococcal population structure in
Nigeria which is consistent with other studies of carried
pneumococcal population in similar settings like The Gambia
and Ghana [43]. As most MLST studies thus far have focused on
pneumococcus isolated in the USA and Europe although most
pneumococcal disease occurs in the developing world [44] this
result is not surprising; hence a considerable portion of the global
diversity of pneumococcal is currently unexplored. Knowledge of
prevailing STs, strains or serotypes to target in a vaccine is crucial
in terms of future vaccine development in Africa because clonal
groupings may differ substantially according to geographical
regions and these varied clonal groupings may predominate at
different periods. For example, the serotype 1-ST 217 identified in
this study belongs to the ST217 clonal complex which predom-
inates in Africa but rare in Europe or US. The ST 217 clonal
complex is one of the most important lethal genotypes implicated
in meningitis outbreaks in Ghana and Burkina Faso [45,46].
We also found evidence of capsular switching in three STs (280,
310 and 5543). After the introduction of the pneumococcal
conjugate vaccine, particular strains with genetic advantage may
change their capsules from vaccine serotypes to non-vaccine
serotype through capsular switching [47,48]. It is important to
enhance surveillance of pneumococcal disease in Africa prior to
routine use of pneumococcal conjugate vaccine to allow the
detection of capsular switching and monitoring of the long-term
effectiveness of the conjugate vaccine in use.
The high frequency of resistance to commonly used antibiotics
is a source of worry especially as TS, to which 93% of isolates were
resistant, is one the WHO recommended first line antibiotic for
treatment for respiratory tract infections in most developing
countries [49]. In many developing countries with high burden of
pneumococci in carriage and disease, high levels of resistance to
TS and TC have also been reported [14,41,50,51]. The pattern of
resistance is not surprising considering these top the list of
antibiotics purchased over the counter that are misused by
caregivers in Nigeria and similar settings. However, it is unclear
how in vitro resistance relates to clinical response to treatment
with TS in pneumococcal disease [52]. Finding almost a third of
isolates resistant to penicillin G (though entirely of the interme-
diate category) is also a cause for concern. This is in contrast to
observations from The Gambia [14] and Kenya [53] where
penicillin resistant pneumococci are not prevalent. This is
probably associated with indiscriminate antibiotic use and poor
regulatory oversight of drug supply including unlimited access to
prescription antibiotics, which Nigeria has in common with other
settings of penicillin resistance. Most of the antimicrobial resistant
isolates were of vaccine-type (96%) and invasive serotypes
suggesting use of PCVs will lower the prevalence of resistant
pneumococci. All the isolates were fully susceptible to erythromy-
cin but the emerging resistance to chloramphenicol especially with
the observed resistance to first-line antimicrobials calls for
intervention.
Age ,5 years [35], concurrent acute respiratory tract
infection [12], household smoke or cooking fuel [54], recent
use of antibiotics [15], and overcrowding [32] are some of the
risk factors that have been associated with pneumococcal
carriage. The only significant individual risk factor for carriage
found in this study was age and this association remained
significant after adjusting for clustering of data. This is consistent
with data from both developing and developed world settings
[12,35,55]. That such risk factors as socioeconomic class and
breast-feeding were not associated with carriage may reflect the
lack of socioeconomic diversity in the study population. In
addition, breastfeeding for prolonged periods is a cultural norm
in this part of the world.
The absence of community age-distribution data during
determination of sample size did not affect our results. The study
did not have sufficient power for serotype specific sub analysis
despite achieving the target sample size. Our risk factor analyses
did not include day care or school attendance so the contribution if
any of this exposure to pneumococcal carriage among children in
this population is still unknown. However, this risk factor was not
associated with carriage in other studies conducted in settings like
ours [14,15]. That people are in crowded environments in these
settings regardless of whether they are at a day care, in school or at
home is the likely explanation for this finding.
In conclusion, carriage of pneumococcus is very high in this
Nigerian community indicating a high burden of pneumococcal
disease. Young age is a major risk factor for carriage. Results from
this study provide much needed data on the profile of prevalent
pneumococcal serotypes and antimicrobial susceptibility patterns
in a well-defined Nigerian population. Further research is required
to quantify the burden of IPD, the serotypes involved, associated
risk factors and outcomes especially as not all serotypes implicated
Pneumococcus in Nigeria: Carriage and Biology
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30548
in IPD are found in carriage. However, data from this study
provides a starting point and baseline for future comparisons.
The consequence of findings from this study, and essential to the
introduction of routine immunization against pneumococcus is the
need for an extensive regional/nationwide surveillance of
pneumococcal carriage, IPD and antimicrobial resistance that
are crucial for vaccination impact assessment. The global vaccine
preventable invasive bacterial disease (VP-IBD’s) 3-tiered ap-
proach to sentinel surveillance should be the model implemented
in Nigeria alongside introduction of PCV-13. This should start
with tier-1 i.e. surveillance for suspected meningitis in children
under five years across the country with rapid expansion to tier-2
level surveillance that includes cases of suspected pneumonia and
septicaemia. Revisions to local antibiotic policy and prescription
practice are required in light of the significant resistance seen to
commonly used antibiotics.
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